off-label use of glp-1 agonists for obesity in 2016 The and Obesity: How Diabetes Drugs are Changing Non-Diabetic Lives — tl;dr pharmacy Frontiers | GLP−1 receptor agonists

doi:10.2337/db15-1255 17

doi: 10.3389/fnins.2019.01112 9 GaoHZengZZhangHZhouXGuanLDengWet al

Survodutide, a glucagon/GLP-1 dual agonist, met its primary endpoint of histological improvement in MASH at 48 weeks and also demonstrated a statistically significant improvement in fibrosis, a secondary endpoint

Note that in the majority of the participants, the weight loss obtained is well above 5% of the initial weight (the minimum associated with an improvement in health) and even exceeds 20% in many of them, in particular in the participants who received tirzepatide

Formulary forum: Exenatide: A new option for the treatment of type 2 diabetes

Although its currently approved for type 2 diabetes, its potential for weight loss is generating significant interest